Healthcare sector analysis: AbbVie, Novo Nordisk, and BridgeBio Pharma

The healthcare and biopharmaceutical sectors are seeing significant activity as companies navigate shifts between legacy treatments and new chronic care therapies. AbbVie Inc. reported FY 2025 revenue of $61.2 billion, with a net income of $4.2 billion and free cash flow totaling $17.8 billion. The company maintains a diverse portfolio in immunology, oncology, and aesthetics, though it faces risks related to customer concentration among major wholesale distributors.

Novo Nordisk A/S continues to focus on metabolic health, specifically through its leadership in diabetes and obesity treatments. Meanwhile, BridgeBio Pharma, Inc. presented at the Wells Fargo 21st Annual Healthcare Conference, highlighting its pipeline. The company reported $8 billion in de-risked peak year sales potential from post-Phase III drugs and an estimated $10 billion in total risk-adjusted sales potential across its entire pipeline.